Latest Conference Articles

Catch up on coverage from the second day of Revolutionizing Atopic Dermatitis.

Bunick provides an overview of the most important highlights from his late-breaking session at RAD 2023.

Jonathan Silverberg, MD, PhD, MPH, shares highlights and key takeaways from his RAD 2023 sessions.

Andrew Blauvelt, MD, MBA, discusses his RAD 2023 session, "Biologics for atopic dermatitis."

Andrew Blauvelt, MD, MBA, shares highlights from his RAD session, "Battle of the Titans 2: Challenging Patient Cases: Who is Eligible for Systemic Treatment in Atopic Dermatitis?"

A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.

Among numerous sessions to be held this weekend at the Revolutionizing Atopic Dermatitis Conference in Washington, DC, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Catch up on coverage from the first day of Revolutionizing Atopic Dermatitis.

Revolutionizing Atopic Dermatitis Conference Chair Jonathan Silverberg, MD, PhD, MPH, previews this weekend's conference in Washington, DC.

When sessions, late-breaking research, and more concludes, there is no shortage of things to do in the nation’s capital.

The 5th annual RAD conference kicks off April 29, 2023, in Washington, DC.

Let us know what content you want to see from RAD.

Click here to answer this week's poll.

Checkpoint inhibitors such as pembrolizumab nivolumab are playing a major role in cancer treatment, but they can also produce adverse events that affect the skin.

From acne and psoriasis to skin cancer and hair loss, leaders in the industry share their quick tips that help save time.

When a patient complains of breast pain, there are several special considerations for diagnosis and treatment.

Check out new, trending, and up-and-coming perspectives on the use of laser therapies in several dermatologic conditions.

Late-breaking positive phase 2a results were presented at AAD 2023.

Click here to answer this week's poll.

More than 300 innovative sessions, an engaging exhibit hall, and heartfelt networking—there was a lot to pack into AAD 2023! Here are the highlights.

Results from the phase 3 DERMIS-1 and DERMIS-2 trials were presented at the 2023 American Academy of Dermatology Annual Meeting.

A pediatric dermatologist and pediatric allergist translated guidelines into clinical practice at AAD 2023.

A pair of phase 3 trials met all primary and secondary endpoints after 48 weeks.

By week 24 of the phase 3 study, a quarter of participants felt their vitiligo had improved.

Jack Arbiser, MD, PhD discusses the connection between the skin barrier and anti-aging products.

Results from the phase 3 study were presented at an AAD late-breaking research session.

A key session at the annual meeting will share practical advice and tools to better support you and your patients.